Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

INTRODUCTION. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vincenzi, Bruno, Santini, Daniele, Russo, Antonio, Addeo, Raffaele, Giuliani, Francesco, Montella, Liliana, Rizzo, Sergio, Venditti, Olga, Frezza, Anna Maria, Caraglia, Michele, Colucci, Giuseppe, Del Prete, Salvatore, Tonini, Giuseppe
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2010
Matèries:
Hepatobiliary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227883/
https://ncbi.nlm.nih.gov/pubmed/20051477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0143
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars